Potential role of serum fetuin-A in relation with pro-inflammatory, chemokine and adhesion molecules in diabetic kidney disease: a case–control study
Inflammatory cytokine, adipokine and adhesion molecules are known to play a key role in pathogenesis of diabetic kidney disease (DKD). In this study, our aim was to investigate the role of fetuin-A in relation with pro-inflammatory cytokines (IL-6, IL-18), adipokines (adiponectin, leptin), chemokine (MCP-1), and adhesion molecules (ICAM-1, VCAM-1) in control and DKD subjects. We recruited a total of 224 type 2 diabetic (T2D) subjects. The control subjects were T2D with a normal albumin excrete (albumin-to-creatinine ratio—ACR ≤ 30 mg/g creatinine) and estimated glomerular filtration rate (eGFR) ≥ 60 (ml/min/1.73 m2), while cases were T2D subjects with albumin excrete (ACR ≥ 30 mg/g creatinine) and eGFR ≤ 60 (ml/min/1.73 m2). FBS, HbA1c, lipid profile (TC, LDL, HDL, triglyceride), ALT, AST, GGT, serum creatinine, BMI, blood pressure was evaluated in all the study subjects. Randox evidence biochip analyzer was used for measuring inflammatory cytokines, adipokines, and adhesion molecules by chemiluminescent assay. Serum fetuin-A and IL-18 were measured by ELISA kits. Serum fetuin-A levels were significantly decreased in DKD cases compare to control group [456.8 (299.2–649.0) µg/ml versus 670.6 (573.0–726.1) µg/ml; p < 0.001)]. Serum fetuin-A levels correlates significantly with IL-6, IL-18, TNF-α, PAI-1, leptin, resistin and ACR (p < 0.001). This study concludes that serum fetuin-A and pro-inflammatory markers (IL-18, IL-6, IL-1α and TNF-α) might play an important role in the pathophysiology and inflammatory process of DKD.
KeywordsDKD T2D ICAM-1 VCAM-1 IL-6 IL-18 Fetuin-A
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The study has been carried out under compliance of ethical issues. The study was approved by the institutional Review Committee of College of Medicine, King Saud University Riyadh. We used the STROBE case–control checklist for writing our report.
Written informed consent was obtained from each subject.
- 1.International Diabetes Federation (IDF) (2017) http://www.diabetesatlas.org/resources/2017-atlas.html. Accessed 28 Jan 2018
- 4.Choudhary N, Ahlawat RS (2008) Interleukin-6 and C-reactive protein in pathogenesis of diabetic nephropathy: new evidence linking inflammation, glycemic control, and microalbuminuria. Iran J Kidney Dis 2:72–79Google Scholar
- 9.Ju H, Zhou Z, Sun M, Ji Y, Zhang J, Chen S, Ji J (2014) Association between serum fetuin A and diabetic nephropathy in patients with type 2 diabetes. Chin J Endocrinol Metab 30(7):592–594Google Scholar
- 15.Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Sonmez A, Eyileten T, Yenicesu M, Oguz Y, Tasar M, Vural A, Ikizler TA, Stenvinkel P, Lindholm B (2008) Serum fetuin-a concentration and endothelial dysfunction in chronic kidney disease. Nephron Clin Pract 108:c233–40. https://doi.org/10.1159/000120209 CrossRefGoogle Scholar
- 16.Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Sonmez A, Cakir E, Oguz Y, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J (2008) Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant 23:1621–1627. https://doi.org/10.1093/ndt/gfm828 CrossRefGoogle Scholar
- 17.Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G (1979) Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 64:1118–1129. https://doi.org/10.1172/jci109551 CrossRefGoogle Scholar
- 19.Gangneux C, Daveau M, Hiron M, Derambure C, Papaconstantinou J, Salier JP (2003) The inflammation-induced down-regulation of plasma Fetuin-A (α2HS-Glycoprotein) in liver results from the loss of interaction between long C/EBP isoforms at two neighbouring binding sites. Nucleic Acids Res 31:5957–5970CrossRefGoogle Scholar
- 20.Wegner M, Araszkiewicz A, Piorunska-Stolzmann M, Wierusz-Wysocka B, Zozulinska-Ziolkiewicz D (2013) Association between IL-6 concentration and diabetes-related variables in DM1 patients with and without microvascular complications. Inflammation 36:723–728. https://doi.org/10.1007/s10753-013-9598-y CrossRefGoogle Scholar
- 23.Wong CK, Ho AW, Tong PC, Yeung CY, Kong AP, Lun SW, Chan JC, Lam CW (2007) Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy. Clin Exp Immunol 149:123–131. https://doi.org/10.1111/j.1365-2249.2007.03389.x CrossRefGoogle Scholar
- 25.Miyauchi K, Takiyama Y, Honjyo J, Tateno M, Haneda M (2009) Upregulated IL-18 expression in type 2 diabetic subjects with nephropathy: TGF-beta1 enhanced IL-18 expression in human renal proximal tubular epithelial cells. Diabetes Res Clin Pract 83:190–199. https://doi.org/10.1016/j.diabres.2008.11.018 CrossRefGoogle Scholar
- 28.Moriwaki Y, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S, Okamura H, Koga M, Fukuchi M, Hada T (2003) Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 52:605–608. https://doi.org/10.1053/meta.2003.50096 CrossRefGoogle Scholar
- 29.Mahmoud RA, el-Ezz SA, Hegazy AS (2004) Increased serum levels of interleukin-18 in patients with diabetic nephropathy. Ital J Biochem 53:73–81Google Scholar
- 34.Axelsson J, Bergsten A, Qureshi AR, Heimbürger O, Barany P, Lönnqvist F, Lindholm B, Nordfors L, Alvestrand A, Stenvinkel P (2006) Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 69:596–604CrossRefGoogle Scholar